BioMarin Q2 revenue beats estimates; raises 2026 outlook

BioMarin Pharmaceutical

06/08/2026 21:13

Overview
US rare disease biotech's Q2 revenue rose 20% yr/yr, beating analyst expectations
Adjusted EPS for Q2 beat consensus as revenue growth helped offset higher Amicus-related costs
Company raised full-year 2026 revenue and adjusted EPS guidance on stronger growth outlook

Outlook
BioMarin raises 2026 total revenue guidance to $3.875 bln-$3.925 bln
Company lifts 2026 VOXZOGO revenue outlook to $1 bln-$1.05 bln
BioMarin increases 2026 non-GAAP diluted EPS forecast to $4.90-$5.10

Result Drivers
AMICUS ACQUISITION - Addition of GALAFOLD and POMBILITI + OPFOLDA, acquired from Amicus, was a primary driver of revenue growth
VOXZOGO DEMAND - Strong global demand for VOXZOGO, with treated children increasing over 20% year-over-year, contributed to revenue growth
PALYNZIQ AND METABOLIC CONDITIONS - Continued strength from PALYNZIQ and growth in metabolic conditions portfolio supported results

Company press release: ID:nPn8QfZw2a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$990 mln
$926.91 mln (21 Analysts)
Q2 Adjusted EPS
Beat
$1.20
$0.69 (15 Analysts)
Q2 EPS
 
$0.23
 
Q2 Net Income
 
$45 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for BioMarin Pharmaceutical Inc. is $87.83, about 46.6% above its August 5 closing price of $59.91
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 11 three months ago

Reuters Recommended Reads
Aug 4 - Ultragenyx Q2 revenue rises 28% to record high, net loss narrows
Aug 5 - Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales
Aug 5 - Mirum Pharmaceuticals Q2 sales rise, lifts outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)